Controversies in osteoporosis management: Antiresorptive therapy for preventing bone loss: When to use one or two antiresorptive agents?

J. Christopher Gallagher, Sri Harsha Tella

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.

Original languageEnglish (US)
Pages (from-to)749-756
Number of pages8
JournalClinical Obstetrics and Gynecology
Volume56
Issue number4
DOIs
StatePublished - Dec 1 2013

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Controversies in osteoporosis management: Antiresorptive therapy for preventing bone loss: When to use one or two antiresorptive agents?'. Together they form a unique fingerprint.

  • Cite this